Search
QS-21
go.drugbank.com/drugs/DB05400InvestigationalAs a vaccine additive, it is currently being evaluated in clinical trials in a variety of disease areas by Antigenics.
Interferon alfa
go.drugbank.com/drugs/DB05258ApprovedInvestigationalWithdrawnNatural interferon alpha or Multiferon is obtained from the leukocyte fraction of human blood following induction with Sendai virus. Interferon alfa contains several naturally occurring IFN-α subtypes and is purified by affinity chromato...
Propylthiouracil
go.drugbank.com/drugs/DB00550ApprovedA thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharma...
Ceftiofur
go.drugbank.com/drugs/DB11485ExperimentalVet approvedIt is marketed by pharmaceutical company Zoetis as Excenel, and is the active ingredient in that company's Specramast LC (lactating cow formula) product. … The metabolite desfurolyceftiofur also has antibiotic activity, consequently the two compounds are measured together to monitor for antibiotic activity in the milk.
Nepafenac
go.drugbank.com/drugs/DB06802ApprovedInvestigationalNepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.
Human Embryonic Stem Cell-derived M Cell
go.drugbank.com/drugs/DB15734InvestigationalCAStem is composed of immunity- and matrix-regulatory cells (IMRCs), also known as M cells, which can be administered through injection.
Butoconazole
go.drugbank.com/drugs/DB00639ApprovedButoconazole is an imidazole antifungal used in gynecology.
Tiotropium
go.drugbank.com/drugs/DB01409ApprovedInvestigational[A180163] Tiotropium was granted FDA approval on 30 January 2004.[L7084]
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune
HGS-TR2J
go.drugbank.com/drugs/DB05895ExperimentalHGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.